Associated tags: Diffusion, Oxygen, Hypoxia, GBM, TSC, Tissue, Nectar Lifesciences, Name, Security (finance), Corporation, Annual, Proxy, Attention, NUALS Arts and Literary Annual Meet, Beneficial ownership, Annual general meeting, Suite, Proxy statement, AND, Innisfree
Locations: CHARLOTTESVILLE, VA, US, PETRA, VIRGINIA
Retrieved on:
Friday, December 16, 2022
Nectar Lifesciences,
TSC,
WHEN,
Diffusion,
Innisfree,
AND,
Proxy statement,
Suite,
GBM,
Annual general meeting,
Beneficial ownership,
NUALS Arts and Literary Annual Meet,
Name,
Attention,
Proxy,
Annual,
Corporation,
Oxygen,
Hypoxia,
Tissue,
Security (finance),
Shareholder CHARLOTTESVILLE, Va., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced that it has entered into a settlement agreement with LifeSci Special Opportunities Master Fund Ltd., affiliated entities and certain related parties (collectively, “LifeSci Special Opportunities”), with respect to, among other things, the membership and composition of the Company’s board of directors (the “Board”), before the Company’s 2022 Annual Meeting of Stockholders (the “Annual Meeting”).
Key Points:
- Under the terms of the agreement, LifeSci Special Opportunities will withdraw its slate of director nominees (the “LifeSci Nominees”) previously nominated for election and vote in favor of the Board’s recommended nominees at the Annual Meeting.
- “We appreciate LifeSci Special Opportunities’ support of our process.”
LifeSci Special Opportunities will not be submitting blue proxy cards for tabulation for the Annual Meeting and encourages stockholders to submit a WHITE proxy card in support of the Board’s recommendations on each proposal.
- LifeSci Special Opportunities, which currently beneficially owns approximately 4.8% of Diffusion’s outstanding shares, in the aggregate, is also subject to certain customary standstill provisions under the terms of the agreement.
- The complete agreement between Diffusion and LifeSci Special Opportunities will be filed on a Form 8-K with the U.S. Securities and Exchange Commission.
Acquisition,
Annual report,
Science,
Sale,
Dechert,
Chairperson,
Annual general meeting,
Consultant,
Eastern Time Zone,
Oxygen,
COVID-19,
Roman Catholic Diocese of La Crosse,
TSC,
Food,
Cancer,
ZERO,
Regulation of tobacco by the U.S. Food and Drug Administration,
Lobbying,
NUALS Arts and Literary Annual Meet,
Knowledge,
Our Boarding House,
ALL,
Innisfree,
CFO,
GBM,
Negotiation,
Exercise,
Science 37,
SPAC,
Tissue,
Nectar Lifesciences,
Particular,
Letter,
Confusion,
Hypoxia,
Auction,
Retail,
Fine chemical,
Holding company,
Security (finance),
Risk management,
Management,
Financial services,
Cryptocurrency,
Airline,
Real estate,
Pharmaceutical industry,
Ammunition,
Shareholder,
Diffusion The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process.
Key Points:
- The letter highlights the strength, experience and quality of the Company’s board of directors as it continues to take steps to unlock stockholder value through a strategic review process.
- Diffusion’s board of directors urges stockholders to vote “FOR” each of its six nominees for director on your WHITE proxy card.
- Our Board has made significant progress to date in its strategic review of opportunities to enhance value for all stockholders.
- Our Board is currently composed of uniquely qualified leaders with public company senior leadership experience, including at the C-level in Fortune 50 companies.
